iBio updates corporate presentation; posts preliminary cash of $8.8M as of June 30, 2025

iBio, Inc.

Preliminary cash of $8.8M as of June 30, 2025; audited FY2025 results expected later this quarter.
IBIO-610 (Activin E antibody) showed 8.9% body weight loss, 26% fat reduction, no lean mass loss in DIO mice.
IBIO-610 + semaglutide achieved 35.3% weight loss vs 27.8% alone; prevented weight regain after GLP-1 cessation.
IBIO-600 (anti-myostatin) half-life 40-52 days in NHPs; human estimate 57-147 days; CMC and GLP tox ongoing.
Partnered with AstralBio to develop amylin receptor agonist antibodies for obesity treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.